212 related articles for article (PubMed ID: 38278146)
61. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
[TBL] [Abstract][Full Text] [Related]
62. Organoid models derived from patients with malignant phyllodes tumor of the breast.
Chu X; Wu M; Yang J; Fu Y; Wang X; Wang H; Xiao Y; Chen D; He J
Breast Cancer Res Treat; 2023 Jul; 200(2):193-201. PubMed ID: 37204665
[TBL] [Abstract][Full Text] [Related]
63. Updates on Organoid Model for the Study of Liver Cancer.
El-Khobar KE; Sukowati CHC
Technol Cancer Res Treat; 2023; 22():15330338231154090. PubMed ID: 36788421
[TBL] [Abstract][Full Text] [Related]
64. Establishment and Long-Term Expansion of Small Cell Lung Cancer Patient-Derived Tumor Organoids.
Choi SY; Cho YH; Kim DS; Ji W; Choi CM; Lee JC; Rho JK; Jeong GS
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572899
[TBL] [Abstract][Full Text] [Related]
65. Disease Modeling on Tumor Organoids Implicates AURKA as a Therapeutic Target in Liver Metastatic Colorectal Cancer.
Boos SL; Loevenich LP; Vosberg S; Engleitner T; Öllinger R; Kumbrink J; Rokavec M; Michl M; Greif PA; Jung A; Hermeking H; Neumann J; Kirchner T; Rad R; Jung P
Cell Mol Gastroenterol Hepatol; 2022; 13(2):517-540. PubMed ID: 34700030
[TBL] [Abstract][Full Text] [Related]
66. Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture.
Abugomaa A; Elbadawy M; Yamanaka M; Goto Y; Hayashi K; Mori T; Uchide T; Azakami D; Fukushima R; Yoshida T; Shibutani M; Yamashita R; Kobayashi M; Yamawaki H; Shinohara Y; Kaneda M; Usui T; Sasaki K
Sci Rep; 2020 Jun; 10(1):9393. PubMed ID: 32523078
[TBL] [Abstract][Full Text] [Related]
67. Plocabulin Displays Strong Cytotoxic Activity in a Personalized Colon Cancer Patient-Derived 3D Organoid Assay.
Costales-Carrera A; Fernández-Barral A; Bustamante-Madrid P; Guerra L; Cantero R; Barbáchano A; Muñoz A
Mar Drugs; 2019 Nov; 17(11):. PubMed ID: 31752287
[TBL] [Abstract][Full Text] [Related]
68. Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions.
van Tienderen GS; Li L; Broutier L; Saito Y; Inacio P; Huch M; Selaru FM; van der Laan LJW; Verstegen MMA
Cancer Cell; 2022 Mar; 40(3):226-230. PubMed ID: 35148815
[TBL] [Abstract][Full Text] [Related]
69. Exploring Tumor-Immune Interactions in Co-Culture Models of T Cells and Tumor Organoids Derived from Patients.
Jeong SR; Kang M
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834057
[TBL] [Abstract][Full Text] [Related]
70. Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma.
Kim SY; Kim SM; Lim S; Lee JY; Choi SJ; Yang SD; Yun MR; Kim CG; Gu SR; Park C; Park AY; Lim SM; Heo SG; Kim H; Cho BC
Clin Cancer Res; 2021 Aug; 27(15):4397-4409. PubMed ID: 34083237
[TBL] [Abstract][Full Text] [Related]
71. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
[TBL] [Abstract][Full Text] [Related]
72. Targeting cancer drug resistance utilizing organoid technology.
Chai C; Ji P; Xu H; Tang H; Wang Z; Zhang H; Zhou W
Biomed Pharmacother; 2023 Feb; 158():114098. PubMed ID: 36528918
[TBL] [Abstract][Full Text] [Related]
73. Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.
de Witte CJ; Espejo Valle-Inclan J; Hami N; Lõhmussaar K; Kopper O; Vreuls CPH; Jonges GN; van Diest P; Nguyen L; Clevers H; Kloosterman WP; Cuppen E; Snippert HJG; Zweemer RP; Witteveen PO; Stelloo E
Cell Rep; 2020 Jun; 31(11):107762. PubMed ID: 32553164
[TBL] [Abstract][Full Text] [Related]
74. An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping.
Kawasaki K; Toshimitsu K; Matano M; Fujita M; Fujii M; Togasaki K; Ebisudani T; Shimokawa M; Takano A; Takahashi S; Ohta Y; Nanki K; Igarashi R; Ishimaru K; Ishida H; Sukawa Y; Sugimoto S; Saito Y; Maejima K; Sasagawa S; Lee H; Kim HG; Ha K; Hamamoto J; Fukunaga K; Maekawa A; Tanabe M; Ishihara S; Hamamoto Y; Yasuda H; Sekine S; Kudo A; Kitagawa Y; Kanai T; Nakagawa H; Sato T
Cell; 2020 Nov; 183(5):1420-1435.e21. PubMed ID: 33159857
[TBL] [Abstract][Full Text] [Related]
75. "Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction".
Papaccio F; García-Mico B; Gimeno-Valiente F; Cabeza-Segura M; Gambardella V; Gutiérrez-Bravo MF; Alfaro-Cervelló C; Martinez-Ciarpaglini C; Rentero-Garrido P; Zúñiga-Trejos S; Carbonell-Asins JA; Fleitas T; Roselló S; Huerta M; Sánchez Del Pino MM; Sabater L; Roda D; Tarazona N; Cervantes A; Castillo J
J Exp Clin Cancer Res; 2023 Jan; 42(1):8. PubMed ID: 36604765
[TBL] [Abstract][Full Text] [Related]
76. High-content, targeted RNA-seq screening in organoids for drug discovery in colorectal cancer.
Norkin M; Ordóñez-Morán P; Huelsken J
Cell Rep; 2021 Apr; 35(3):109026. PubMed ID: 33882314
[TBL] [Abstract][Full Text] [Related]
77. [Establishment of a living biobank : Improved guidance of precision cancer care with in vitro and in vivo cancer models].
Pauli C; Moch H; Rubin MA
Pathologe; 2017 Nov; 38(Suppl 2):160-168. PubMed ID: 28956107
[TBL] [Abstract][Full Text] [Related]
78. Human liver organoids for disease modeling of fibrolamellar carcinoma.
Narayan NJC; Requena D; Lalazar G; Ramos-Espiritu L; Ng D; Levin S; Shebl B; Wang R; Hammond WJ; Saltsman JA; Gehart H; Torbenson MS; Clevers H; LaQuaglia MP; Simon SM
Stem Cell Reports; 2022 Aug; 17(8):1874-1888. PubMed ID: 35803261
[TBL] [Abstract][Full Text] [Related]
79. Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy.
Narasimhan V; Wright JA; Churchill M; Wang T; Rosati R; Lannagan TRM; Vrbanac L; Richardson AB; Kobayashi H; Price T; Tye GXY; Marker J; Hewett PJ; Flood MP; Pereira S; Whitney GA; Michael M; Tie J; Mukherjee S; Grandori C; Heriot AG; Worthley DL; Ramsay RG; Woods SL
Clin Cancer Res; 2020 Jul; 26(14):3662-3670. PubMed ID: 32376656
[TBL] [Abstract][Full Text] [Related]
80. Ex vivo chemosensitivity assay using primary ovarian cancer organoids for predicting clinical response and screening effective drugs.
Ito Y; Kondo J; Masuda M; Matsuzaki S; Onuma K; Kanda M; Watanabe Y; Sakaguchi H; Yoshino K; Ueda Y; Kamiura S; Kimura T; Inoue M
Hum Cell; 2023 Mar; 36(2):752-761. PubMed ID: 36474106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]